CoChat

Guidelines on the management of arterial hypertension and related comorbidities in Latin America

Open access
· 2017 · Journal of Hypertension
Cited by 73

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Univ Hosp, Hypertens & Metab Unit, Fdn Favaloro, Belgrano 1782 P 4, RA-1093 Buenos Aires, DF, Argentina

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hjh.0000000000001418

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Research works printed but not linked: 75

  1. Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
  2. Mengue, 2016, Acesso e uso de medicamentos para hipertensão arterial no Brasil, Rev Saude Publica, 50, 1s
  3. Oliveira Araujo, 2014, Access to antihypertensive agents in Brazil: evaluation of the ‘Health Has No Price’ program, Clin Ther, 36, 1191, 10.1016/j.clinthera.2014.06.003 · doi:10.1016/j.clinthera.2014.06.003
  4. Hernández-Hernández, 2010, Hypertension in seven Latin American cities: the Cardiovascular Risk Factor MultipleEvaluation in Latin America (CARMELA) study, J Hypertens, 28, 24, 10.1097/HJH.0b013e328332c353 · DOI · Paper page
  5. Schargrodsky, 2008, CARMELA: assessment of cardiovascular risk in seven Latin American cities, Am J Med, 121, 58, 10.1016/j.amjmed.2007.08.038 · DOI · Paper page
  6. Teo, 2009, The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries, Am Heart J, 158, 1, 10.1016/j.ahj.2009.04.019 · DOI · Paper page
  7. Chow, 2013, Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries, JAMA, 310, 959, 10.1001/jama.2013.184182 · DOI · Paper page
  8. Lopez Jaramillo, 2013, Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome, J Hypertens, 31, 223, 10.1097/HJH.0b013e32835c5444 · DOI · Paper page
  9. Alegre Diaz, 2016, Diabetes and cause-specific mortality in Mexico City, N Engl J Med, 17, 1961, 10.1056/NEJMoa1605368 · DOI · Paper page
  10. Holwerda, 2016, Arterial baroreflex control of sympathetic nerve activity and heart rate in patients with type 2 diabetes, Am J Physiol Heart Circ Physiol, 311, H1170, 10.1152/ajpheart.00384.2016 · DOI
  11. Gupta, 2016, Predictors of sleep disorders among patients with type 2 diabetes mellitus, Diabetes Metab Syndr, 10, 213, 10.1016/j.dsx.2016.06.009 · DOI
  12. DePace, 2014, Cardiac autonomic testing and diagnosing heart disease. ‘A clinical perspective’, Heart Int, 9, 37
  13. Sempertegui, 2011, Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador, Public Health Nutr, 14, 758, 10.1017/S1368980010002636 · DOI
  14. Alvarez, 2010, Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America, Braz J Infect Dis, 14, 256, 10.1016/S1413-8670(10)70053-2 · DOI
  15. Bermudez, 2010, The Maracaibo city metabolic syndrome prevalence study: design and scope, Am J Ther, 17, 288, 10.1097/MJT.0b013e3181c121bc · DOI
  16. Escobedo, 2009, Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study, Cardiovasc Diabetol, 26, 8
  17. Caceres, 2008, Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity, BMC Pediatr, 8, 1, 10.1186/1471-2431-8-31 · DOI
  18. Royer, 2007, The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women, Climacteric, 10, 164, 10.1080/13697130701258895 · DOI
  19. Garcia, 2007, Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome, Int J Cardiol, 122, 176, 10.1016/j.ijcard.2006.11.058 · DOI
  20. Alberti, 2009, Harmonizing the metabolic syndrome: a Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 · DOI · Paper page
  21. Spence, 1996, Cerebral consequences of hypertension, J Hypertens, 14, S139
  22. Porcello Marrone, 2013, Risk factors among stroke subtypes Brazil, J Stroke Cerebrovasc Dis, 22, 32, 10.1016/j.jstrokecerebrovasdis.2011.05.022 · DOI
  23. De Jesús Llibre, 2010, Prevalence of stroke and associated risk factors in older adults in Havana city and Matanzas province, Cuba, MEDICC Rev, 12, 20, 10.37757/MR2010.V12.N3.6 · DOI
  24. Lanas, 2014, Cardiovascular disease in Latin America: the growing epidemic, Progr Cardiovasc Dis, 57, 262, 10.1016/j.pcad.2014.07.007 · DOI
  25. Manolio, 1994, Magnetic resonance abnormalities and cardiovascular disease in older adults: the Cardiovascular Health Study, Stroke, 25, 318, 10.1161/01.STR.25.2.318 · DOI · Paper page
  26. Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 · DOI · Paper page
  27. Lanas, 2007, Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study, Circulation, 115, 1067, 10.1161/CIRCULATIONAHA.106.633552 · DOI · Paper page
  28. Dokainish, 2016, Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study, Int J Cardiol, 204, 133, 10.1016/j.ijcard.2015.11.183 · DOI · Paper page
  29. Rodriguez, 2010, Left ventricular mass and ventricular remodelling among Hispanic subgroups compared with non-Hispanic blacks and whites MESA (Multi-Ethnic Study of Atherosclerosis), J Am Coll Cardiol, 55, 234, 10.1016/j.jacc.2009.08.046 · DOI · Paper page
  30. Bocchi, 2013, The reality of heart failure in Latin America, J Am Coll Cardiol, 62, 949, 10.1016/j.jacc.2013.06.013 · doi:10.1016/j.jacc.2013.06.013
  31. Sacco, 2001, Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study, Stroke, 32, 1725, 10.1161/01.STR.32.8.1725 · DOI · Paper page
  32. Cowley, 1996, The role of the kidney in hypertension, JAMA, 275, 1581, 10.1001/jama.1996.03530440061038 · DOI · Paper page
  33. Textor, 2005, Atherosclerotic renal artery stenosis: how big is the problem and what happens if nothing is done?, J Hypertens, 23, s5, 10.1097/01.hjh.0000192096.83302.02 · doi:10.1097/01.hjh.0000192096.83302.02
  34. Krumme, 1996, Diagnosis of renovascular disease by intra- and extrarenal Doppler scanning, Kidney Int, 50, 1288, 10.1038/ki.1996.440 · DOI · Paper page
  35. Safian, 2001, Renal-artery stenosis, N Engl J Med, 344, 431, 10.1056/NEJM200102083440607 · DOI · Paper page
  36. Plouin, 1998, Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. EssaiMulticentrique Medicaments vs Angioplastie (EMMA) Study Group, Hypertension, 31, 823, 10.1161/01.HYP.31.3.823 · DOI · Paper page
  37. Rosa-Diez, 2014, Renal replacement therapy in Latin American end-stage renal disease, Clin Kidney J, 7, 431, 10.1093/ckj/sfu039 · doi:10.1093/ckj/sfu039
  38. Murabito, 1997, Intermittent claudication: a risk profile from the Framingham Heart Study, Circulation, 96, 44, 10.1161/01.CIR.96.1.44 · DOI · Paper page
  39. Bertomeu, 2008, Prevalence and prognostic influence of peripheral arterial disease in patients 40 years old admitted into hospital following an acute coronary event, Eur J Vasc Endovasc Surg, 36, 189, 10.1016/j.ejvs.2008.02.004 · DOI
  40. Ingolfsson, 1994, A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968–1986: a strong relationship to smoking and serum cholesterol the Reykjavik Study, J Clin Epidemiol, 47, 1237, 10.1016/0895-4356(94)90128-7 · DOI
  41. Sanchez, 2009, Latin American guidelines on hypertension, J Hypertens, 27, 905, 10.1097/HJH.0b013e32832aa6d2 · DOI · Paper page
  42. Mancia, 2011, Diagnosis and management of patients with white-coat and masked hypertension, Nat Rev Cardiol, 8, 686, 10.1038/nrcardio.2011.115 · DOI
  43. Longo, 2005, Masked hypertension in adults, Blood Press Monit, 10, 307, 10.1097/00126097-200512000-00004 · DOI
  44. Ho, 2014, Long-term cardiovascular risks associated with an elevated heart rate: the Framingham Heart Study, J Am Heart Assoc, 3, e000668, 10.1161/JAHA.113.000668 · DOI · Paper page
  45. Palatini, 2016, Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the European Society of Hypertension, J Hypertens, 34, 813, 10.1097/HJH.0000000000000865 · DOI · Paper page
  46. Kang, 2015, Accuracy of home versus ambulatory blood pressure monitoring in the diagnosis of white-coat and masked hypertension, J Hypertens, 33, 1580, 10.1097/HJH.0000000000000596 · DOI
  47. Grotto, 2008, Hypertension and socio-economic status, Curr Opin Cardiol, 23, 335, 10.1097/HCO.0b013e3283021c70 · DOI · Paper page
  48. Flescher, 2008, Social patterning of chronic disease risk factors in a Latin American city, J Urban Health, 85, 923, 10.1007/s11524-008-9319-2 · DOI
  49. Lopez-Jaramillo, 2016, Is it time to reappraise blood pressure thresholds and targets? Position Statement of the Latin American Society of Hypertension, Hypertension, 68, 257, 10.1161/HYPERTENSIONAHA.116.07738 · DOI
  50. James, 2014, 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8), JAMA, 311, 507, 10.1001/jama.2013.284427 · DOI · Paper page
  51. Weber, 2014, Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension, J Hypertens, 32, 3, 10.1097/HJH.0000000000000065 · DOI · Paper page
  52. Lonn, 2016, Blood pressure lowering in intermediate risk persons without cardiovascular disease, N Engl J Med, 374, 2009, 10.1056/NEJMoa1600175 · DOI · Paper page
  53. Parati, 2017, SPRINT blood pressure; sprinting back to Smirk's basal blood pressure?, Hypertension, 69, 15, 10.1161/HYPERTENSIONAHA.116.08216 · DOI
  54. Thomopoulos, 2016, Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs. discontinuations because of adverse drug events – meta-analyses of randomized trials, J Hypertens, 34, 1451, 10.1097/HJH.0000000000000972 · DOI · Paper page
  55. Fagard, 2011, Exercise therapy in hypertensive cardiovascular disease, Prog Cardiovasc Dis, 53, 404, 10.1016/j.pcad.2011.03.006 · DOI
  56. Leong, 2015, Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) Study, Lancet, 836, 266, 10.1016/S0140-6736(14)62000-6 · DOI · Paper page
  57. Thomopoulos, 2015, Effects of blood pressure lowering on outcome incidence in hypertension 5. Head-to-head comparisons of various classes of antihypertensive drugs. Overview and meta-analyses, J Hypertens, 33, 1321, 10.1097/HJH.0000000000000614 · DOI · Paper page
  58. Thomopoulos, 2014, Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk-overview and meta-analyses of randomized trials, J Hypertens, 32, 2305, 10.1097/HJH.0000000000000380 · DOI · Paper page
  59. Gupta, 2010, Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis, Hypertension, 55, 399, 10.1161/HYPERTENSIONAHA.109.139816 · DOI · Paper page
  60. Patel, 2016, Improved blood pressure control to reduce cardiovascular disease morbidity and mortality: the Standardized Hypertension Treatment and Prevention Project, J Clin Hypertens, 18, 1284, 10.1111/jch.12861 · DOI · Paper page
  61. Khatib, 2016, Availability and affordability of cardiovascular disease medicines and their effect on use in high income, middle income and low income countries: an Analysis of the PURE Study Data, Lancet, 387, 61, 10.1016/S0140-6736(15)00469-9 · DOI · Paper page
  62. 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group., BMJ, 317, 703, 10.1136/bmj.317.7160.703 · DOI · Paper page
  63. Cederholm, 2012, Blood pressure and risk of cardiovascular disease in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP-II), J Hypertens, 30, 2020, 10.1097/HJH.0b013e3283577bdf · DOI
  64. Bigazzi, 1998, Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension, J Hypertens, 16, 1325, 10.1097/00004872-199816090-00014 · DOI · Paper page
  65. Jensen, 2000, Arterial hypertension, microalbuminuria and risk of ischemic heart disease, Hypertension, 35, 898, 10.1161/01.HYP.35.4.898 · DOI · Paper page
  66. Arnlov, 2005, Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study, Circulation, 112, 969, 10.1161/CIRCULATIONAHA.105.538132 · DOI · Paper page
  67. Bonadonna, 2016, Novel antidiabetic drugs and cardiovascular risk: primum non nocere, Nutr Metab Cardiovasc Dis, 26, 759, 10.1016/j.numecd.2016.05.007 · DOI
  68. Son, 2015, Dipeptidyl Peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies, Diabetes Metab J, 39, 373, 10.4093/dmj.2015.39.5.373 · DOI
  69. Abdul-Ghani, 2016, SGLT-2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG outcome Study, Diabetes Care, 39, 715, 10.2337/dc16-0041 · DOI · Paper page
  70. Pfeifer, 2017, Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis, Cardiovasc Diabetol, 16, 29, 10.1186/s12933-017-0511-0 · DOI · Paper page
  71. Peek, 1996, Hypertension in pregnancy: which method of blood pressure measurement is most predictive of outcome?, Obstet Gynecol, 88, 1030, 10.1016/S0029-7844(96)00350-X · DOI
  72. Ferrazzani, 1990, Proteinuria and outcome of 444 pregnancies complicated by hypertension, Am J Obstet Gynecol, 162, 366, 10.1016/0002-9378(90)90387-M · DOI · Paper page
  73. Wilson, 2002, Molecular epidemiology of preeclampsia, Obstet Gynecol Surv, 58, 39, 10.1097/00006254-200301000-00022 · DOI · Paper page
  74. Redmond, 2011, Health behaviors and racial disparity in blood pressure control in the national health and nutrition examination survey, Hypertension, 57, 383, 10.1161/HYPERTENSIONAHA.110.161950 · DOI · Paper page
  75. Fuchs, 2011, Why do black Americans have higher prevalence of hypertension? An enigma still unsolved, Hypertension, 57, 379, 10.1161/HYPERTENSIONAHA.110.163196 · DOI

Cited by

See all 73

Metadata

Venue
Journal of Hypertension
Published
2017-08
Volume
35
Issue
8
Pages
1529-1545
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2782397703
Cited by
73
References
26
FWCI
5.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines on the management of arterial hypertension and related comorbidities in Latin America. https://app.cochat.ai/papers/10.1097/hjh.0000000000001418
The paper
Guidelines on the management of arterial hypertension and related comorbidities in Latin America. (2017). Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000001418

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.